Data / Drug companies / Leading Pharma, LLC
Leading Pharma, LLC: 85 products in the FDA NDC directory, labeler code 69315
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Leading Pharma, LLC (labeler code 69315) lists 85 products in the FDA National Drug Code Directory, covering 41 finished drugs by generic name. By type: 85 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 20, 2026.
The request: Watch Leading Pharma, LLC (FDA labeler code 69315): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 69315
- Products in commercial distribution
- 85
- Packages
- 149
- Finished drugs by generic name
- 41
- Prescription products
- 85
- Over the counter products
- 0
- Controlled substance products
- Schedule III 2, Schedule IV 6, Schedule V 2
- Flagged as original packager
- 78 of 78 products that carry the flag
- Started marketing in the last 12 months
- 5
- Earliest marketing start
- February 1, 2006
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 81 | 95.3% |
| Authorized generics (NDA) | 2 | 2.4% |
| Other unapproved drugs | 2 | 2.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 85 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 31 | 36.5% |
| Capsule | 13 | 15.3% |
| Tablet, film coated | 11 | 12.9% |
| Solution | 11 | 12.9% |
| Solution/ drops | 4 | 4.7% |
| Tablet, extended release | 3 | 3.5% |
| Capsule, delayed release | 2 | 2.4% |
| Suspension | 2 | 2.4% |
| Ointment | 1 | 1.2% |
| Powder, for solution | 1 | 1.2% |
| Injection, powder, lyophilized, for solution | 1 | 1.2% |
| Kit | 1 | 1.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Pilocarpine hydrochloride | 69315-316 | Solution/ drops | Generic drugs (ANDA) | October 20, 2026 |
| Pilocarpine hydrochloride | 69315-315 | Solution/ drops | Generic drugs (ANDA) | October 20, 2026 |
| Pilocarpine hydrochloride | 69315-314 | Solution/ drops | Generic drugs (ANDA) | October 20, 2026 |
| Frovatriptan succinate | 69315-157 | Tablet, film coated | Generic drugs (ANDA) | February 28, 2026 |
| Ethacrynate sodium | 69315-701 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 9, 2026 |
| Gatifloxacin | 69315-331 | Solution | Generic drugs (ANDA) | October 6, 2025 |
| Carbinoxamine maleate | 69315-239 | Tablet | Generic drugs (ANDA) | August 1, 2025 |
| Oxazepam | 69315-913 | Capsule | Generic drugs (ANDA) | July 9, 2025 |
| Oxazepam | 69315-912 | Capsule | Generic drugs (ANDA) | July 9, 2025 |
| Oxazepam | 69315-911 | Capsule | Generic drugs (ANDA) | July 9, 2025 |
| Prochlorperazine maleate | 69315-266 | Tablet, film coated | Generic drugs (ANDA) | June 25, 2025 |
| Prochlorperazine maleate | 69315-265 | Tablet, film coated | Generic drugs (ANDA) | June 25, 2025 |
| Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution | 69315-330 | Solution | Generic drugs (ANDA) | May 29, 2025 |
| Metformin hydrochloride er | 69315-410 | Tablet, extended release | Generic drugs (ANDA) | May 1, 2025 |
| Difluprednate | 69315-329 | Emulsion | Generic drugs (ANDA) | February 18, 2025 |
| Timolol maleate | 69315-325 | Solution | Generic drugs (ANDA) | November 7, 2024 |
| Phenylephrine hydrochloride | 69315-324 | Solution | Generic drugs (ANDA) | September 5, 2024 |
| Phenylephrine hydrochloride | 69315-323 | Solution | Generic drugs (ANDA) | September 5, 2024 |
| Allopurinol | 69315-409 | Tablet | Generic drugs (ANDA) | September 1, 2024 |
| Ofloxacin | 69315-327 | Solution | Generic drugs (ANDA) | July 15, 2024 |
| Ketorolac Tromethamine | 69315-322 | Solution/ drops | Generic drugs (ANDA) | June 1, 2024 |
| Allopurinol | 69315-292 | Tablet | Generic drugs (ANDA) | May 1, 2024 |
| Allopurinol | 69315-291 | Tablet | Generic drugs (ANDA) | May 1, 2024 |
| Ofloxacin | 69315-320 | Solution | Generic drugs (ANDA) | March 1, 2024 |
| Ketorolac tromethamine | 69315-260 | Tablet, film coated | Generic drugs (ANDA) | March 1, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.